目的对比探讨盐酸氨溴索与肺表面活性物质治疗新生儿呼吸窘迫综合征的疗效。方法回顾性分析2009年3月-2011年4月新生儿科诊断为呼吸窘迫综合征的124例患儿的临床资料，124例患儿随机分为两组，分别采用盐酸氨溴索静脉滴注和肺表面活性物质替代疗法。对比两组患儿并发症发生率和病死率。结果两组患儿均出现各种并发症，但并发症发生率无统计学差异，肺表面活性物质组病死率较低。结论盐酸氨溴索具有价廉、安全性高的优点，而肺表面活性物质起效快。但两者对新生儿呼吸窘迫综合征疗效无显著差异。%Objective To contrast the effect of ambroxol hydrochloride and pulmonary surfactant in the treatment of neonatal respiratory distress syndrome. Methods 124 cases from March 2009 to April 2011 in the with respiratory distress syndrome were analyzed.124 patients were randomly divided into two groups, respectively ambroxol hydrochloride intravenously and pulmonary surfactant replacement therapy. Compare the differences of the two groups of children morbidity and mortality. Results The two groups of children there are a variety of complications, but no signiifcant difference in the incidence of complications, lower mortality rates in lung surfactant therapy group. Conclusion Ambroxol hydrochloride has the advantages of low cost, high security, and has the advantages of rapid onset pulmonary surfactant. But both of neonatal respiratory distress syndrome was no signiifcant difference.
展开▼
